Rachel E. Haurwitz Buys 20,000 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) Stock

Caribou Biosciences, Inc. (NASDAQ:CRBU) CEO Rachel E. Haurwitz bought 20,000 shares of the business’s stock in a transaction on Friday, March 14th. The shares were acquired at an average price of $1.02 per share, for a total transaction of $20,400.00. Following the completion of the purchase, the chief executive officer now owns 3,369,395 shares in the company, valued at approximately $3,436,782.90. The trade was a 0.60 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Caribou Biosciences Stock Performance

Shares of Caribou Biosciences stock opened at $0.95 on Thursday. Caribou Biosciences, Inc. has a one year low of $0.95 and a one year high of $5.77. The stock’s fifty day moving average is $1.32 and its 200 day moving average is $1.75. The stock has a market cap of $88.44 million, a P/E ratio of -0.58 and a beta of 2.34.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Monday, March 10th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.08 million for the quarter, compared to analysts’ expectations of $2.11 million. Analysts predict that Caribou Biosciences, Inc. will post -1.64 EPS for the current year.

Analyst Ratings Changes

CRBU has been the topic of several recent analyst reports. Bank of America cut their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Citigroup lowered their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a report on Wednesday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $10.33.

Hedge Funds Weigh In On Caribou Biosciences

Institutional investors have recently bought and sold shares of the stock. PFM Health Sciences LP raised its holdings in Caribou Biosciences by 5.5% during the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after acquiring an additional 223,299 shares during the period. JPMorgan Chase & Co. raised its holdings in Caribou Biosciences by 475.9% during the fourth quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company’s stock valued at $3,969,000 after acquiring an additional 2,062,563 shares during the period. Schonfeld Strategic Advisors LLC raised its holdings in Caribou Biosciences by 28.4% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company’s stock valued at $3,360,000 after acquiring an additional 467,738 shares during the period. Geode Capital Management LLC raised its holdings in Caribou Biosciences by 6.5% during the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after acquiring an additional 124,782 shares during the period. Finally, FMR LLC raised its holdings in Caribou Biosciences by 7.4% during the third quarter. FMR LLC now owns 1,581,493 shares of the company’s stock valued at $3,100,000 after acquiring an additional 109,606 shares during the period. 77.51% of the stock is owned by institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.